Abstract: Provided is a radiotherapeutic agent, including a composite particle, which is obtained by binding a molecule that specifically recognizes a target to a substrate particle including titanium peroxide, and which generates reactive oxygen through irradiation with a radiation. Further, because the radiotherapeutic agent contains the molecule that specifically recognizes a target, the radiotherapeutic agent has a function of accumulating in the target. The radiotherapeutic agent is capable of enhancing effects of radiotherapy, and is capable of reducing side effects on a living body to efficiently attack the target.

Abstract: A method for producing a deformed shaped particles comprising step of: absorbing a polymerizable vinyl type monomer contained in an aqueous emulsion in a seed particles and polymerizing an absorbed polymerizable vinyl type monomer, wherein the seed particles are a resin particles which are derived from a (meth)acrylic ester having an ester part containing at least an alkyl group with a number of carbon atoms of 3 or more and less than 6, and which have a weight average molecular weight of 150000 to 1000000 (measured by GPC: gel permeation chromatography) and the polymerizable vinyl type monomer contains 5 to 50 wt. % of a crosslinkable monomer to the entire amount of the polymerizable vinyl type monomer.

Abstract: The present disclosure describes a replacement for petroleum jelly as a base for products which is suitable for most any application for which petroleum jelly can be used. The jelly is a glycerine based jelly composition comprising; vegetable derived glycerine and an emulsifier, wherein the emulsifier can be any known and/or commercially available glucoside containing emulsifier. Other suitable emulsifiers together with glycerine and essential or vegetable based oils with or without inorganic fillers may also be added to the jelly to impart fragrance, color, UVA and UVB sun protection factor(s), immuno-enhancing aromatherapeutics, as well as free radical scavenging constituents. In addition, temperature stabilizers and stiffening agents such as waxes and other inorganic fillers including silica and clays may also be added during manufacture as required. The glycerine is preferably present in the range of 50-95%.

Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.

Abstract: The present invention is a cosmetic for eyelashes characteristically comprising modified cross-section hollow fibers. What is preferable is a cosmetic for eyelashes characteristically containing said modified cross-section hollow fibers that are polygonal cross-section hollow fibers having depressions so they can orient along the eyelashes wherein the length of the hollow fibers is 0.5-4 mm and the size is 20-50 ?m. The object of the present invention is to provide a cosmetic for eyelashes that exhibits a superior curling effect and long lash effect and allows a beautiful finish.

Abstract: Pharmaceutical compositions are provided for the pharmacological treatment of breathing disorders and, more specifically, to compositions containing agents having serotonin receptor modulating activity for the alleviation of sleep apnea (central and obstructive) and other sleep-related breathing disorders wherein the active ingredients are released such as to extend effective blood plasma concentrations across the period of sleep.

Abstract: The present invention relates to processes for forming particles including drugs in a solution, changing the bulk or surface properties of a drug particle, and/or microencapsulating drug particles, and compositions produced thereby. In some embodiments, the process described utilizes mechanical agitation, more specifically low-frequency sonication, under controlled conditions, which provides mild shear forces during forming and/or precipitation to control the particle growth and mixing properties. Particle size can range from less than about 200 nanometers to greater than about one millimeter, depending on the processing conditions and application.

Abstract: A pharmaceutical composition contains tolterodine L-tartrate stabilized against degradation with an acid. Acid-stabilized tolterodine L-tartrate may be used to make various types of immediate release and controlled release dosage forms.

Abstract: A delivery device that allows for the sustained release of an agent, particularly useful for the sustained release of a therapeutic agent to limited access regions, such as the posterior chamber of the eye and inner ear. The delivery device is minimally invasive, refillable and may be easily fixed to the treatment area. The delivery device includes a hollow body with an inlet port at its proximal end for insertion of the agent, a reservoir for holding the agent and a delivery mechanism for the sustained delivery of the agent from the reservoir to the patient.

Abstract: Polymeric indicator films and pH indicating wraps are provided for visually monitoring, detecting, and/or determining the presence of metabolic byproducts from harmful or potentially harmful microorganisms. Also provided are methods of use and preparation of the polymeric indicator films.

Abstract: This invention relates to a process to facilitate osteochondral bone remodeling in a subject by inducing regeneration of this bone to a healthy, vascularized state capable of supporting the underlying hyaline cartilage of articular joints and spinal discs, both biomechanically and metabolically and to deliver a bioactive agent. This process involves the steps of: administering an effective amount of an injectable in situ curing biomaterial composite to a site. The biomaterial composite product is prepared by a process involving the steps: admixing an alginate solution with a nonporous aggregate of ?-tricalcium phosphate, in a sufficient amount to initiate polymerization of the alginate solution, to form a hydrogel having from between 10 to 20 percent by volume of ?-tricalcium phosphate.

Abstract: Provided is a cosmetic including silicone microparticles, in which the silicone microparticles include 100 parts by mass of silicone elastomer spherical microparticles having a volume average particle diameter within a range from 0.1 to 100 ?m, and 0.5 to 25 parts by mass of a polyorganosilsesquioxane that coats a surface of the silicone elastomer spherical microparticles, and the silicone elastomer is capable of absorbing not less than 30 parts by mass of at least one oily substance selected from the group consisting of sebum, hydrocarbon oils and ester oils per 100 parts by mass of the silicone elastomer. Even if containing an unctuous agent, the cosmetic exhibits favorable feelings upon use, with no spreading difficulties, stickiness, greasiness, oily film feeling, or the like, and is also capable of suppressing problems caused by sebum, namely, changes in the makeup cosmetic properties of the cosmetic, changes in the color of the cosmetic, increased shine, and the like.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: A non-gelatin encapsulation system for liquid filled soft capsules, by nature of the carrier, the cationic-ionic balance of the carrier and the active ingredients, or the concentration of the active ingredients and excipients, are difficult or impossible to commercially encapsulate in gelatin capsules. In particular, the system is adapted for the encapsulation of highly basic, or alkaline, fills. The system provides for a predominantly starch and gelling carrageenan based shell, which displays high resistance to both concentrated fills and to alkaline fills, in particular, to those fills which contain the salt or salts of weak acids and strong bases.

Abstract: A composition having at least one fatty phase containing at least one resin having a number-average molecular weight of less than or equal to 10 000 g/mol chosen from rosin, rosin derivatives and hydrocarbon-based resins, and mixtures thereof, at least one volatile oil, and at least one phenyl silicone oil. The composition according to the invention makes it possible to obtain a homogeneous and comfortable deposit on the lips or the skin, which has in particular improved properties of staying power of the colour and of the gloss.

Abstract: The invention refers to a method for the production of cellulose sulfate which is completely water-soluble and has an adjustable solution viscosity in aqueous solution, which qualifies the produced sodium cellulose sulfate (SCS) as auxiliary material with ideal biological compatibility for biological and medical applications, in particular it is suitable for the encapsulation and immobilization of biological objects, e.g. tissue, cells, microorganisms, enzymes or viruses in microcapsule.

Abstract: The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.

Abstract: An object of the present invention is to provide a composition for promoting sleep, which any one can safely take on a daily basis without any risks of adverse action. In addition, an object of the present invention is to provide food and a medicament, comprising the above-mentioned composition, having an effect for promoting sleep for an individual having sleep disorders. Further, an object of the present invention is to provide a method for promoting sleep comprising administering theanine to an individual having sleep disorders, and use of theanine for preparation of the food or medicament for an individual having sleep disorders.

Abstract: The present invention provides a hair cosmetic composition contains (A) a di-long-chain cationic surfactant represented by formula (1); (B) an ethylene oxide adduct of 1,2-alkanediol represented by formula (2) and/or an N-acyl-N-methylmonoethanolamide represented by formula (3); and (C) a hydrophobicized alkyl cellulose represented by formula (4) and/or a cationic polymer represented by formula (5), and (D) water (chemical formulas not shown). The hair cosmetic composition has remarkably high safety and excellent stability. In addition, the composition exhibits excellent spreadability over hair upon application thereof and can finish hair with suppleness and less stickiness. Also, even when the composition has a low base material content, a lamellar liquid crystal structure can be formed.

Abstract: The invention relates to a method for producing medicaments that contain vardenafil hydrochloride, essentially as trihydrate in solid form, and to medicaments that can be obtained according to this method.